639 related articles for article (PubMed ID: 27539936)
1. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.
Petrosino S; Di Marzo V
Br J Pharmacol; 2017 Jun; 174(11):1349-1365. PubMed ID: 27539936
[TBL] [Abstract][Full Text] [Related]
2. A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation.
Esposito E; Impellizzeri D; Bruschetta G; Cordaro M; Siracusa R; Gugliandolo E; Crupi R; Cuzzocrea S
Eur J Pharmacol; 2016 Jul; 782():107-18. PubMed ID: 27095683
[TBL] [Abstract][Full Text] [Related]
3. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels.
Petrosino S; Schiano Moriello A; Cerrato S; Fusco M; Puigdemont A; De Petrocellis L; Di Marzo V
Br J Pharmacol; 2016 Apr; 173(7):1154-62. PubMed ID: 25598150
[TBL] [Abstract][Full Text] [Related]
4. N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.
Skaper SD; Facci L; Barbierato M; Zusso M; Bruschetta G; Impellizzeri D; Cuzzocrea S; Giusti P
Mol Neurobiol; 2015 Oct; 52(2):1034-42. PubMed ID: 26055231
[TBL] [Abstract][Full Text] [Related]
5. The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
Impellizzeri D; Peritore AF; Cordaro M; Gugliandolo E; Siracusa R; Crupi R; D'Amico R; Fusco R; Evangelista M; Cuzzocrea S; Di Paola R
FASEB J; 2019 Oct; 33(10):11364-11380. PubMed ID: 31344333
[TBL] [Abstract][Full Text] [Related]
6. Palmitoylethanolamide in CNS health and disease.
Mattace Raso G; Russo R; Calignano A; Meli R
Pharmacol Res; 2014 Aug; 86():32-41. PubMed ID: 24844438
[TBL] [Abstract][Full Text] [Related]
7. Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia.
Cordaro M; Impellizzeri D; Siracusa R; Gugliandolo E; Fusco R; Inferrera A; Esposito E; Di Paola R; Cuzzocrea S
Toxicol Appl Pharmacol; 2017 Aug; 329():231-240. PubMed ID: 28610993
[TBL] [Abstract][Full Text] [Related]
8. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
Impellizzeri D; Bruschetta G; Cordaro M; Crupi R; Siracusa R; Esposito E; Cuzzocrea S
J Neuroinflammation; 2014 Aug; 11():136. PubMed ID: 25164769
[TBL] [Abstract][Full Text] [Related]
9. Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects.
Scuderi C; Bronzuoli MR; Facchinetti R; Pace L; Ferraro L; Broad KD; Serviddio G; Bellanti F; Palombelli G; Carpinelli G; Canese R; Gaetani S; Steardo L; Steardo L; Cassano T
Transl Psychiatry; 2018 Jan; 8(1):32. PubMed ID: 29382825
[TBL] [Abstract][Full Text] [Related]
10. Ultramicronized N-palmitoylethanolamine associated with analgesics: Effects against persistent pain.
Nobili S; Micheli L; Lucarini E; Toti A; Ghelardini C; Di Cesare Mannelli L
Pharmacol Ther; 2024 Jun; 258():108649. PubMed ID: 38615798
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets.
Peritore AF; Siracusa R; Crupi R; Cuzzocrea S
Nutrients; 2019 Sep; 11(9):. PubMed ID: 31514292
[TBL] [Abstract][Full Text] [Related]
12. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis.
Paladini A; Fusco M; Cenacchi T; Schievano C; Piroli A; Varrassi G
Pain Physician; 2016 Feb; 19(2):11-24. PubMed ID: 26815246
[TBL] [Abstract][Full Text] [Related]
13. Palmitoylethanolamide: A Natural Compound for Health Management.
Clayton P; Hill M; Bogoda N; Subah S; Venkatesh R
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069940
[TBL] [Abstract][Full Text] [Related]
14. Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man.
Caltagirone C; Cisari C; Schievano C; Di Paola R; Cordaro M; Bruschetta G; Esposito E; Cuzzocrea S;
Transl Stroke Res; 2016 Feb; 7(1):54-69. PubMed ID: 26706245
[TBL] [Abstract][Full Text] [Related]
15. Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives.
Kriek R
Inflammopharmacology; 2014 Jun; 22(3):195-8. PubMed ID: 24647619
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials.
Marcucci M; Germini F; Coerezza A; Andreinetti L; Bellintani L; Nobili A; Rossi PD; Mari D
Trials; 2016 Jul; 17():369. PubMed ID: 27473188
[TBL] [Abstract][Full Text] [Related]
17. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy.
Gabrielsson L; Mattsson S; Fowler CJ
Br J Clin Pharmacol; 2016 Oct; 82(4):932-42. PubMed ID: 27220803
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.
Artukoglu BB; Beyer C; Zuloff-Shani A; Brener E; Bloch MH
Pain Physician; 2017 Jul; 20(5):353-362. PubMed ID: 28727699
[TBL] [Abstract][Full Text] [Related]
19. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.
Skaper SD; Facci L; Giusti P
Mol Neurobiol; 2013 Oct; 48(2):340-52. PubMed ID: 23813098
[TBL] [Abstract][Full Text] [Related]
20. A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
Britti D; Crupi R; Impellizzeri D; Gugliandolo E; Fusco R; Schievano C; Morittu VM; Evangelista M; Di Paola R; Cuzzocrea S
BMC Vet Res; 2017 Aug; 13(1):229. PubMed ID: 28768536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
